Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients

The nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib significantly improved survival in metastatic colorectal cancer patients (mCRC). Both treatments are characterized by different treatment-related adverse events but detailed analyses of predictive side effects...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Med
Päätekijät: Unseld, Matthias, Fischöder, Sebastian, Jachs, Mathias, Drimmel, Magdalena, Siebenhüner, Alexander, Bianconi, Daniela, Kieler, Markus, Puhr, Hannah, Minichsdorfer, Christoph, Winder, Thomas, Prager, Gerald W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356853/
https://ncbi.nlm.nih.gov/pubmed/32517383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9061772
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia